Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review



    Explore by Goal












     Quick Explanation


    Critique in one pass: This FEBS Journal review is a useful, structured gateway to plasma-membrane SLCs (structure/folds, regulation, and cancer/drug-transport relevance), but it remains inherently limited by being a narrative synthesis with uneven mechanistic depth across families and by relying on incomplete human localization/structure data.




     Long Explanation


    Paper Review (visual-first): β€œA guide to plasma membrane solute carrier proteins” (10.1111/febs.15531)

    Authors: Mattia D. Pizzagalli; Ariel Bensimon; Giulio Superti-Furga. Journal: FEBS Journal (2020).
    Type: narrative review (no new primary datasets).

    1) What the review claims (and what’s actually substantiated)

    • Scope/definition: The review frames SLCs as one of four major transporter superfamilies (ABC, ATPases, ion channels, SLCs) and focuses on SLCs at the plasma membrane.
    • Size of SLC universe: It reports β€œ458 transport proteins in 65 families.”
    • Plasma-membrane fraction: It reports ~60% of SLC proteins with known localization are annotated at the plasma membrane.
    • Mechanistic generalization risk: It emphasizes alternating-access as a common mechanism for many secondary-active SLCs, but notes regulation via PTMs, trafficking, and interaction networks complicate prediction of behavior a priori.
    • Orphans remain: It reports that estimates suggest up to ~30% of SLC proteins remain orphan (no known substrate).

    2) Evidence-weighted β€œbig picture” visuals from the paper’s stated numbers

    These visuals only encode explicit quantitative claims stated in the article text provided.
    TM-domain fraction comes from the statement that most (~83%) tend to contain between 7 and 12 TM domains.

    3) Mechanistic themes: what’s strong vs what’s easy to overgeneralize

    Strength: clear taxonomy + structural β€œfold” anchors
    • The review anchors many SLC families to common folds (notably MFS and LeuT-like) and summarizes several alternating-access modalities (rocker-switch, rocking-bundle, elevator).
    Caution: structural mechanism β‰  in vivo phenotype
    • The review explicitly notes that predicting SLC behavior is difficult because of regulation via PTMs, trafficking, and interaction partners (and that differences can alter specificity/activity).
    • It also states that high-resolution structures exist for only a few human SLC proteins, so many insights rely on homologs and modeling, with the additional caveat that homologous proteins may lack cytoplasmic tail features relevant for activity/specificity.
    Interpretation bias check (skeptical): cancer links are associative
    • The review repeatedly positions changes in transporter expression/localization as enabling cancer metabolism and progression; however, because this is a narrative synthesis, causal inference depends on heterogenous primary studies with varying model systems, and the paper itself highlights major mechanistic gaps (including incomplete plasma-membrane localization knowledge).

    4) Best-use β€œdecision tree” for readers (based on the paper’s organization)

    A quick navigation map for using this review effectively.
    This map reflects the review’s stated flow: family definition β†’ structural features/mechanisms β†’ regulation β†’ plasma-membrane family survey β†’ disease/cancer/drug implications.

    5) Reproducibility & data availability (what you can and can’t verify)

    • No primary data: This is a synthesis without new experimental datasets or deposited accessions.
    • Reproducibility depends on review selection: Because it is narrative, readers cannot fully audit which studies were prioritized beyond the reference list; mechanistic strength varies family-to-family depending on how well the field is experimentally resolved.

    6) Scientific quality β€œwhere it’s strongest” vs β€œwhere it’s weakest”

    Synthesis is strong when it (i) cleanly defines terms, (ii) uses explicit quantitative statements, (iii) admits uncertainty, and (iv) ties structure to mechanism with caveats. It is weaker when (i) mechanistic statements are generalized without quantifying effect sizes across models, and (ii) β€œcancer relevance” remains correlational across heterogeneous systems.

    7) What would most improve this guide (high-impact gaps)

    • Standardize β€œplasma-membrane evidence quality”: The review emphasizes incomplete localization knowledge; a reader-facing evidence tiering system (e.g., human localization strength vs model-system-only) would reduce overgeneralization risk.
    • Separate transport vs β€œtransceptor” / signaling roles: It discusses transporter-independent/remote sensing hypotheses; a more explicit evidence grading between direct transport requirements vs receptor-like signaling would help readers avoid mechanistic conflation.
    • Quantify effect sizes where possible: Cancer-associated claims often rely on differential expression and functional knockdown/inhibition in diverse models; quantifying directionality and effect magnitude would strengthen decision-making for downstream research planning.


    Feedback:    

    Updated: April 21, 2026

     BGPT Paper Review


    Study Novelty

    60%

    Moderately novel as a synthesis: it is not introducing new transporter mechanisms or new datasets, but it provides a consolidated plasma-membrane–focused guide across many SLC families with structural and cancer/drug context. Novelty comes from the specific emphasis/curation angle rather than new theory or results.


    Scientific Quality

    80%

    High-quality as an educational map: clear scope, consistent framing of transport physics (facilitative vs secondary-active), structural fold/motif level descriptions, and explicit acknowledgment of limitations (incomplete localization, few human structures, reliance on homologs/modeling). Lower reproducibility because it is narrative and effect sizes/causality are not systematically quantified across families.


    Study Generality

    80%

    Broadly general for transport-biology learners and cross-family concept building (TM-domain heuristics, fold-based mechanistic categories, regulation principles). Less general for direct experimental design because family-level details vary in mechanistic resolution and in human plasma-membrane evidence strength.


    Study Usefulness

    90%

    Very useful as a starting framework for plasma-membrane SLC selection, mechanistic categorization (facilitative/secondary-active; alternating-access modalities), and for understanding how transporter biology links to cancer metabolism and drug pharmacokinetics.


    Study Reproducibility

    40%

    Low reproducibility in the strict sense because it is a narrative review with no primary dataset, no analysis pipeline, and no standardized evidence-tiering rubric for mechanistic claims across families. One can reproduce the text’s claims only by re-following the cited literature selection.


    Explanatory Depth

    80%

    Mechanistic depth is strong at the structural/transport-principle level (folds; alternating access; TM-domain heuristics; regulation via PTMs/trafficking). It is less deep at predictive quantitative level and causal specificity in cancer contexts, which the review itself frames as complex and incompletely resolved.


    🎁 Authors: Collect 221 Free Science Tokens (β‰ˆ $22.1 USD)

    Claim My Author Tokens

    Use for 55 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $22.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Build an SLC-family feature table from the review’s explicit structural/regulatory categories and classify families by evidence type (PM-localization strength, transport mechanism). Then generate a heatmap for rapid hypothesis triage.



     Hypothesis Graveyard


    A single transporter (e.g., one β€œmaster” SLC) explains most cancer metabolic rewiring via direct effects on proliferation; this is less favored because the review emphasizes network-level integration, redundancy/overlap, and regulatory complexity across many SLC families.


    All SLC cancer associations are purely correlative with no mechanistic causal link; this is weakened by the review’s repeated discussion of transporter-dependent roles in metabolism and drug transport/uptake pathways and known mechanistic examples, even though effect sizes/causality vary.

     Science Art


    Paper Review: A guide to plasma membrane solute carrier proteins Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending